| Identification | Back Directory | [Name]
sodium:4-[(1R,2R,3aS,8bS)-2-hydroxy-1-[(E,3S)-3-hydroxy-4-methyloct-1-en-6-ynyl]-2,3,3a,8b-tetrahydro-1H-cyclopenta[b][1]benzofuran-5-yl]butanoate | [CAS]
496807-11-5 | [Synonyms]
Beraprost sodium (Relative stereochemistry)
sodium:4-[(1R,2R,3aS,8bS)-2-hydroxy-1-[(E,3S)-3-hydroxy-4-methyloct-1-en-6-ynyl]-2,3,3a,8b-tetrahydro-1H-cyclopenta[b][1]benzofuran-5-yl]butanoate | [Molecular Formula]
C24H29NaO5 | [MOL File]
496807-11-5.mol | [Molecular Weight]
420.474 |
| Hazard Information | Back Directory | [Biological Activity]
Beraprost sodium, a prostacyclin analog, is a stable and orally active PGI2 prodrug. It is an effective vasodilator, which has the potential to study pulmonary hypertension by dilating renal blood vessels and improving microcirculation. | [in vitro]
Beraprost sodium (0.1, 1.0, and 10.0 μM; 24 hours) treatment leads to a significant increase in the number of tube formation, BPS plays an important role on angiogenic activity. Beraprost sodium (0.1, 1.0, and 10.0 μM; 24 hours) treatment let VE-cadherin at regions of cell–cell contact becomes more abundant and the morphology of endothelial cells tends to be normal compared with those cultured under hypoxia conditions. < /b> | [in vivo]
Beraprost sodium (oral adminstration; 0.6 mg/kg; once daily; 3 or 7 days) can mitigate the development of renal interstitial fibrosis, decrease renal oxidative stress through its potential vasodilation effect, and further prevent renal interstitial fibrosis . | Animal Model: | 6-8-week-old C57Bl/6J Male Mice | | Dosage: | 0.6 mg/kg | | Administration: | Oral adminstration; 0.6 mg/kg; once daily; 3 or 7 days | | Result: < /td> | Mitigated the development of renal interstitial fibrosis. | | [target]
prodrug of PGI2; Vasodilator | [storage]
Store at -20°C |
|
| Company Name: |
TOSUN PHARM
|
| Tel: |
020-61855200 13326451905 |
| Website: |
www.toref.cn/ |
|